What's in Lycera Corp.'s pipeline?

Lycera Corp. has 3 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 2 in Phase 1.

Which companies overlap with Lycera Corp.'s portfolio?

Top competitors by shared drug class: Actavis Mid-Atlantic LLC, Active Biotech AB, Air Force Military Medical University, China, Astellas Pharma Inc, Bayer.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/lycera-corp.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

Lycera Corp. — Portfolio Competitive Intelligence Brief

Lycera Corp. pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Actavis Mid-Atlantic LLC · 1 shared drug class
Active Biotech AB · 1 shared drug class
Air Force Military Medical University, China · 1 shared drug class
Astellas Pharma Inc · 1 shared drug class
Bayer · 1 shared drug class
Beijing Children's Hospital · 1 shared drug class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 shared drug class
ALK-Abelló A/S · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lycera Corp.:

Cite this brief

Drug Landscape (2026). Lycera Corp. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lycera-corp. Accessed 2026-05-14.